Tuniu News reported on August 27th that the biopharmaceutical company $Trinity Biotech (TRIB.US)$ rose more than 81% in pre-market trading today. As of the time of publication, the stock is up 81.77% at $3.69, with pre-market trading volume reaching $4.1321 million.
On the news front, the company announced on Monday that it has received a significant amount of additional orders for TrinScreen HIV test kits. Due to strong demand and expanded production capacity, the expected sales revenue for TrinScreen HIV in 2024 has been raised from the previous $8 million to approximately $10 million.
TrinScreen HIV is a disposable rapid immunodiagnostic assay for the qualitative detection of antibodies to type 1 and type 2 human immunodeficiency viruses (HIV) in serum, plasma, and whole blood (venipuncture and fingerstick samples).
About the company
Trinity Biotech is a commercial stage biotechnology company focusing on human diagnostics and diabetes management solutions, including wearable biological sensors.
Related Links:Press Release
Risk warning
There is no limit to the rise and fall of the US stock market, and small-cap stocks are more prone to violent fluctuations. Investors need to be alert to risks.